Skip to main content
. Author manuscript; available in PMC: 2012 Aug 31.
Published in final edited form as: Cell. 2012 Feb 3;148(3):421–433. doi: 10.1016/j.cell.2012.01.017

Figure 2. Resveratrol Increases NAD+ Levels and Sirt1 Activity via Epac1.

Figure 2

(A) NAD+, NADH, and NAD+/NADH ratio measured in cells treated with resveratrol and transfected with either control siRNA or Epac1 siRNA (n = 4).

(B) Deacetylation of PGC-1α induced by resveratrol in the presence of either control siRNA or Epac1 siRNA (left). Quantification of PGC-1α acetylation/total PGC-1α is shown in the right panel (n = 3–4).

(C) mtDNA copy number in C2C12 myotubes after 3–4 days of treatment with 007 (10 μM) (n = 4).

(D) Oxygen consumption rate (OCR) in C2C12 myotubes 6 hr after treatment with 007 (10 μM, left), resveratrol (50 μM), rolipram (Rol, 25 μM), or vehicle (Veh) (n = 3).

(E) Change in oxygen consumption rate (DOCR) in C2C12 with palmitoleate injection (100–400 μM) after 6 hr treatment with 007 (10 μM, left), resveratrol (50 μM), rolipram (25 μM), or vehicle (n = 3).

(F) ROS levels in C2C12 myotubes treated with 007 (10 μM) for the indicated times (n = 4). Results are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ****p < 0.0001 compared to the negative control or vehicle-treated samples.